Cargando…
Targeting VEGFR1- and VEGFR2-expressing non-tumor cells is essential for esophageal cancer therapy
Increasing appreciation of tumor heterogeneity and the tumor-host interaction has stimulated interest in developing novel therapies that target both tumor cells and tumor microenvironment. Bone marrow derived cells (BMDCs) constitute important components of the tumor microenvironment. In this study,...
Autores principales: | Xu, Wen Wen, Li, Bin, Lam, Alfred KY, Tsao, Sai Wah, Law, Simon YK, Chan, Kwok Wah, Yuan, Qiu Ju, Cheung, Annie LM |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359332/ https://www.ncbi.nlm.nih.gov/pubmed/25595897 |
Ejemplares similares
-
MicroRNA‐338‐5p reverses chemoresistance and inhibits invasion of esophageal squamous cell carcinoma cells by targeting Id‐1
por: Han, Liang, et al.
Publicado: (2019) -
Significance of serglycin and its binding partners in autocrine promotion of metastasis in esophageal cancer
por: Zhu, Yun, et al.
Publicado: (2021) -
Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway
por: Li, Bin, et al.
Publicado: (2014) -
Novel peptides suppress VEGFR-3 activity and antagonize VEGFR-3-mediated oncogenic effects
por: Chang, Yi-Wen, et al.
Publicado: (2014) -
Circulating CD133(+)VEGFR2(+) and CD34(+)VEGFR2(+) cells and arterial function in patients with beta-thalassaemia major
por: Cheung, Yiu-fai, et al.
Publicado: (2011)